Related Experiment Video

Updated: Jan 8, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.5K

Systemic inflammation in gout and the impact of treat-to-target urate-lowering therapy

Austin M Wheeler1,2, Tanner J Ourada1,2, Spencer Q Jones1,2

  • 1VA Nebraska-Western Iowa Health Care System, Omaha, NE.

Rheumatology (Oxford, England)
|December 14, 2025
PubMed

Insights

Individuals with gout exhibit distinct inflammatory biomarker patterns. Effective urate-lowering therapy (ULT) significantly reduces these inflammatory markers over time, approaching levels seen in non-gout controls.

Area of Science:

  • Rheumatology and Immunology
  • Biomarker Discovery
  • Systemic Inflammation Research

Background:

  • Gout is associated with systemic inflammation, indicated by circulating inflammatory biomarkers.
  • The impact of effective urate-lowering therapy (ULT) on these systemic inflammatory patterns in gout patients is not fully understood.

Purpose of the Study:

  • To determine if distinct circulating inflammatory biomarker patterns differentiate individuals with gout from non-gout controls.
  • To investigate whether highly-effective urate-lowering therapy (ULT) attenuates these biomarker differences over time.

Main Methods:

  • A case-control and longitudinal cohort study design was employed.
  • Serum samples from gout patients and non-gout controls were analyzed for 20 pre-selected inflammatory and cardiometabolic biomarkers.
  • Principal component analysis (PCA) and generalized estimating equations were used to generate an inflammatory score and assess changes over time.

Main Results:

  • Five principal components (PCs) of inflammatory biomarkers differed significantly between gout patients and controls at baseline.
  • Gout patients exhibited significantly higher mean inflammatory scores compared to controls across all time points.
  • Treatment with ULT led to a significant reduction in inflammatory scores at 24 and 48 weeks compared to baseline in gout patients.

Conclusions:

  • Gout is characterized by unique circulating inflammatory biomarker profiles.
  • Treat-to-target ULT effectively mitigates systemic inflammation in gout patients over time, bringing biomarker patterns closer to those of controls.
  • This highlights the importance of ULT in gout management for both flare prevention and reducing systemic inflammation.
Abstract

Keywords:
biomarkersgoutinflammationurate-lowering therapy

More Related Videos

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

778
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.4K

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
445
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
424
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
445
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
459
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
1.1K
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
175